Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial

Research output: Contribution to journalArticle

Standard

Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial. / Eisen, T; Oudard, S; Szczylik, C; Gravis, G; Heinzer, H; Middleton, R; Cihon, F; Anderson, S; Shah, S; Bukowski, R; Escudier, B; Porfiri, Emilio; Target Study group.

In: Journal of the National Cancer Institute, Vol. 100, No. 20, 15.10.2008, p. 1454-63.

Research output: Contribution to journalArticle

Harvard

Eisen, T, Oudard, S, Szczylik, C, Gravis, G, Heinzer, H, Middleton, R, Cihon, F, Anderson, S, Shah, S, Bukowski, R, Escudier, B, Porfiri, E & Target Study group 2008, 'Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial', Journal of the National Cancer Institute, vol. 100, no. 20, pp. 1454-63. https://doi.org/10.1093/jnci/djn319

APA

Eisen, T., Oudard, S., Szczylik, C., Gravis, G., Heinzer, H., Middleton, R., Cihon, F., Anderson, S., Shah, S., Bukowski, R., Escudier, B., Porfiri, E., & Target Study group (2008). Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial. Journal of the National Cancer Institute, 100(20), 1454-63. https://doi.org/10.1093/jnci/djn319

Vancouver

Author

Eisen, T ; Oudard, S ; Szczylik, C ; Gravis, G ; Heinzer, H ; Middleton, R ; Cihon, F ; Anderson, S ; Shah, S ; Bukowski, R ; Escudier, B ; Porfiri, Emilio ; Target Study group. / Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial. In: Journal of the National Cancer Institute. 2008 ; Vol. 100, No. 20. pp. 1454-63.

Bibtex

@article{6be4f0f5f97e44aab73045690a234d9e,
title = "Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial",
abstract = "BACKGROUND: The perception that older cancer patients may be at higher risk than younger patients of toxic effects from cancer therapy but may obtain less clinical benefit from it may be based on the underrepresentation of older patients in clinical trials and the known toxic effects of cytotoxic chemotherapy. It is not known how older patients respond to targeted therapy. METHODS: This retrospective subgroup analysis of data from the phase 3, randomized Treatment Approach in Renal Cancer Global Evaluation Trial examined the safety and efficacy of sorafenib in older (age >or=70 years, n = 115) and younger patients (age or=70 years) and younger (",
author = "T Eisen and S Oudard and C Szczylik and G Gravis and H Heinzer and R Middleton and F Cihon and S Anderson and S Shah and R Bukowski and B Escudier and Emilio Porfiri and {Target Study group}",
year = "2008",
month = oct,
day = "15",
doi = "10.1093/jnci/djn319",
language = "English",
volume = "100",
pages = "1454--63",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "20",

}

RIS

TY - JOUR

T1 - Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial

AU - Eisen, T

AU - Oudard, S

AU - Szczylik, C

AU - Gravis, G

AU - Heinzer, H

AU - Middleton, R

AU - Cihon, F

AU - Anderson, S

AU - Shah, S

AU - Bukowski, R

AU - Escudier, B

AU - Porfiri, Emilio

AU - Target Study group

PY - 2008/10/15

Y1 - 2008/10/15

N2 - BACKGROUND: The perception that older cancer patients may be at higher risk than younger patients of toxic effects from cancer therapy but may obtain less clinical benefit from it may be based on the underrepresentation of older patients in clinical trials and the known toxic effects of cytotoxic chemotherapy. It is not known how older patients respond to targeted therapy. METHODS: This retrospective subgroup analysis of data from the phase 3, randomized Treatment Approach in Renal Cancer Global Evaluation Trial examined the safety and efficacy of sorafenib in older (age >or=70 years, n = 115) and younger patients (age or=70 years) and younger (

AB - BACKGROUND: The perception that older cancer patients may be at higher risk than younger patients of toxic effects from cancer therapy but may obtain less clinical benefit from it may be based on the underrepresentation of older patients in clinical trials and the known toxic effects of cytotoxic chemotherapy. It is not known how older patients respond to targeted therapy. METHODS: This retrospective subgroup analysis of data from the phase 3, randomized Treatment Approach in Renal Cancer Global Evaluation Trial examined the safety and efficacy of sorafenib in older (age >or=70 years, n = 115) and younger patients (age or=70 years) and younger (

U2 - 10.1093/jnci/djn319

DO - 10.1093/jnci/djn319

M3 - Article

C2 - 18840822

VL - 100

SP - 1454

EP - 1463

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 20

ER -